THANK YOU FOR SUBSCRIBING
By apacciooutlook | Monday, December 03, 2018
SEOUL: Seegene- a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics- announces its collaboration agreement with Hologic- a manufacturer and supplier of diagnostic products, medical imaging systems and surgical products- to promote and supply high multiplex real-time PCR (Polymerase Chain Reaction) reagents.
Seegene is manufacturing multiplex assays based on DPO (Dual Priming Oligonucleotide), TOCE, and MuDT (Multiple Detection Temperatures) technologies for the upcoming Hologic Panther Fusion system- the next generation molecular diagnostics platform. MuDT technology provides perfection of qPCR technology by simultaneously identifying and quantifying multipletargets in a single fluorescence channel. Panther Fusion system is a fully automated sample-to-answer instrument, which automates all aspects of nucleic acid testing on a single, integrated platform, eliminating the need for batch processing.
The collaboration aims to provide laboratory customers a perfect evolution of their Panther system and allow expanded assay menu with real-time PCR capabilities in a single-unit-dose format. Seegene's multiplex reagents will enable simultaneous detection and quantification of various target genes, while Hologic will obtain worldwide commercialization rights to the assays.
"Our agreement with Hologic represents another meaningful milestone to Seegene's global expansion initiatives in the molecular diagnostics market. We expect to accelerate technological standardization in the MDx market by building up capabilities of assay development applying on various platforms,” says Dr. Jong - Yoon Chun, Founder and CEO, Seegene.